Asher Mullard

13.5k total citations · 4 hit papers
604 papers, 9.9k citations indexed

About

Asher Mullard is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Reproductive Medicine. According to data from OpenAlex, Asher Mullard has authored 604 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Molecular Biology, 74 papers in Public Health, Environmental and Occupational Health and 73 papers in Reproductive Medicine. Recurrent topics in Asher Mullard's work include Science, Research, and Medicine (73 papers), Pharmaceutical Economics and Policy (44 papers) and Biotechnology and Related Fields (44 papers). Asher Mullard is often cited by papers focused on Science, Research, and Medicine (73 papers), Pharmaceutical Economics and Policy (44 papers) and Biotechnology and Related Fields (44 papers). Asher Mullard collaborates with scholars based in Canada, United Kingdom and United States. Asher Mullard's co-authors include Rujun Kang, Kun Huang, Anat Yanai, Pamela Arstikaitis, Roshni R. Singaraja, Michael R. Hayden, Alaa El-Husseini, Martina Metzler, Brendan Haigh and Claire‐Anne Gutekunst and has published in prestigious journals such as Nature, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Asher Mullard

568 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA approves 100th monoclonal antibody product

2021 347 citations Asher Mullard Nature Reviews Drug Discovery profile →
Targeted protein degraders crowd into the clinic

2021 276 citations Asher Mullard Nature Reviews Drug Discovery profile →
2023 FDA approvals

2024 73 citations Asher Mullard Nature Reviews Drug Discovery profile →
2024 FDA approvals

2025 21 citations Asher Mullard Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Asher Mullard Canada	53	4.9k	2.1k	1.3k	1.0k	870	604	9.9k
Duxin Sun United States	61	8.3k 1.7×	3.3k 1.6×	1.4k 1.1×	422 0.4×	782 0.9×	281	14.9k
Qi Zhao China	52	4.3k 0.9×	3.1k 1.5×	2.4k 1.9×	1.0k 1.0×	706 0.8×	373	12.4k
Anton Simeonov United States	65	8.4k 1.7×	1.5k 0.7×	807 0.6×	366 0.4×	2.4k 2.7×	298	14.1k
Dong Wang China	57	8.5k 1.7×	3.9k 1.8×	1.9k 1.5×	303 0.3×	567 0.7×	548	15.9k
William G. Bornmann United States	66	7.7k 1.6×	3.6k 1.7×	1.2k 0.9×	1.0k 1.0×	432 0.5×	167	14.7k
Chu Wang China	43	6.4k 1.3×	1.1k 0.5×	629 0.5×	727 0.7×	602 0.7×	245	9.8k
Cheng Luo China	51	8.4k 1.7×	1.3k 0.6×	982 0.8×	212 0.2×	988 1.1×	457	12.7k
Léonardo Scapozza Switzerland	43	3.6k 0.7×	874 0.4×	811 0.6×	461 0.5×	523 0.6×	187	7.4k
Bissan Al‐Lazikani United Kingdom	30	8.0k 1.6×	1.2k 0.6×	774 0.6×	1.1k 1.1×	3.7k 4.3×	58	11.2k
Merrill J. Egorin United States	66	5.9k 1.2×	5.5k 2.6×	645 0.5×	409 0.4×	323 0.4×	380	14.2k

Countries citing papers authored by Asher Mullard

Since Specialization

Citations

This map shows the geographic impact of Asher Mullard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Mullard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Mullard more than expected).

Fields of papers citing papers by Asher Mullard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asher Mullard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Mullard. The network helps show where Asher Mullard may publish in the future.

Co-authorship network of co-authors of Asher Mullard

This figure shows the co-authorship network connecting the top 25 collaborators of Asher Mullard. A scholar is included among the top collaborators of Asher Mullard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asher Mullard. Asher Mullard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Mullard, Asher. (2025). Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot. Nature Reviews Drug Discovery. 24(12). 897–897. 1 indexed citations

2.

Mullard, Asher. (2025). “It’s about time”: Tregs win the Nobel prize. Nature Reviews Drug Discovery. 24(12). 900–901.

3.

Mullard, Asher. (2025). FDA approves 100th small-molecule kinase inhibitor. Nature Reviews Drug Discovery. 24(12). 891–895. 1 indexed citations

4.

Mullard, Asher. (2025). Bluebird Bio’s cut-price sale highlights challenges for gene therapy field. Nature Reviews Drug Discovery. 24(4). 239–239.

5.

Mullard, Asher. (2025). FDA approves siRNA drug for haemophilia prophylaxis. Nature Reviews Drug Discovery. 24(5). 322–322.

6.

Mullard, Asher. (2025). FDA approves TROP2-targeted antibody–drug conjugate for breast cancer. Nature Reviews Drug Discovery. 24(3). 159–159. 4 indexed citations

7.

Mullard, Asher. (2024). Chromatin-targeted drug discovery at “a very special moment”. Nature Reviews Drug Discovery. 23(7). 490–491. 2 indexed citations

8.

Mullard, Asher. (2024). FDA approves gene therapy for metachromatic leukodystrophy, the tenth for a genetic disease and the priciest yet. Nature Reviews Drug Discovery. 23(5). 328–328. 1 indexed citations

9.

Mullard, Asher. (2024). FDA approves first complement factor D inhibitor. Nature Reviews Drug Discovery. 23(5). 329–329. 3 indexed citations

10.

Mullard, Asher. (2024). Muscarinic receptor modulators for schizophrenia attract multibillion-dollar attention. Nature Reviews Drug Discovery. 23(2). 96–97. 2 indexed citations

11.

Mullard, Asher. (2024). Radiopharmaceuticals garner continued M&A investments. Nature Reviews Drug Discovery. 23(2). 97–97. 2 indexed citations

12.

Mullard, Asher. (2024). FDA approves 21-valent pneumococcal vaccine. Nature Reviews Drug Discovery. 23(8). 572–572. 3 indexed citations

13.

Mullard, Asher. (2024). GSK’s first-in-class antibiotic secures another phase III win, approaches regulatory run. Nature Reviews Drug Discovery. 23(4). 239–239. 1 indexed citations

14.

Mullard, Asher. (2024). Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease. Nature Reviews Drug Discovery. 23(9). 650–650. 1 indexed citations

15.

Mullard, Asher. (2023). FDA approves first oral drug for postpartum depression, but rejects it for major depressive disorder. Nature Reviews Drug Discovery. 22(10). 774–774. 11 indexed citations

16.

Mullard, Asher. (2023). Massive misuse of chemical probes undermines the utility of these tools. Nature Reviews Drug Discovery. 22(8). 611–611.

17.

Mullard, Asher. (2023). Obesity drug scores landmark cardiovascular win. Nature Reviews Drug Discovery. 22(10). 775–775. 1 indexed citations

18.

Mullard, Asher. (2021). The Nobel Prize-winning path from oxygen sensing research to new drugs. Nature Reviews Drug Discovery. 20(10). 732–733. 2 indexed citations

19.

Mullard, Asher. (2015). Making way for maternal immunization. Nature Reviews Drug Discovery. 15(1). 3–4. 6 indexed citations

20.

Mullard, Asher. (2007). Silent mutations turn up the volume. Nature Reviews Molecular Cell Biology. 8(2). 98–98. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact